Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD5305 | PARP | TargetMol
AstraZeneca's second-generation PARP inhibitor AZD5305 is applied for ...
AZD5305 inhibits and traps selectively PARP1 in cells. A, Left ...
AZD5305 / AstraZeneca
新一代 PARP 抑制剂！阿斯利康 AZD5305 国内启动临床_Insight_奥拉帕利_数据库
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression ...
AZD5305 (Saruparib; AZD-5305) | CAS 2589531-76-8 | AbMole BioScience ...
(PDF) The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma ...
Effect of AZD5305 on PARP2 retention on DNA. (A) The crystal structure ...
AZD5305 has reduced hematological toxicity in monotherapy and ...
AZD5305 selectively targets cancer cells with HRR-deficiency, inducing ...
PK/PD/efficacy relationship of AZD5305 in a BRCA1m TNBC xenograft tumor ...
Medchemexpress LLC HY-132167 5mg , AZD5305 CAS:2589531-76-8 Purity:>98% ...
Study of AZD5305 Alone and with Other Cancer Drugs for Patients with ...
AZD5305 + Darolutamide for Prostate Cancer Clinical Trial 2024 | Power
AZD5305 for Prostate Cancer Clinical Trial 2024 | Power
Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 ...
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other ...
Antitumor efficacy of AZD5305 in combination with carboplatin in vivo ...
Module 2: AZD5335 + AZD5305 for Lung Adenocarcinoma Clinical Trial 2023 ...
Saruparib (AZD5305) | PARP inhibitor | Mechanism | Concentration
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条__新浪财经
How does AstraZeneca's PARP inhibitor differentiate?
恒瑞PARP1抑制剂出海带来的思考|抑制剂|首付款|实体瘤|恒瑞|专利|肿瘤|临床|-健康界
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and ...
AACR 2022: PETRA: First in class, first in human trial of the next ...
Preclinical Characterization of AZD5305, A Next-Generation, Highly ...
RCSB PDB - 9ETQ: Crystal structure of PARP1 catalytic domain bound to ...
Saruparib (AZD5305) | PARP Inhibitor | MedChemExpress
口服PARP1抑制剂AZD5305(Saruparib)治疗乳腺癌、胰腺癌、卵巢癌等,约50%的晚期肿瘤缩小-无癌家园
Medchem story behind the discovery of PARP-1 selective inhibitor ...
Abstract CT007: PETRA: First in class, first in human trial of the next ...
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
AZD-5305 | 2589531-76-8
PARP赛道新势力：氟唑帕利、帕米帕利、AZD5305 2020年12月14， 恒瑞 开发的PARP抑制剂氟唑帕利正式获得NMPA批准上市 ...
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl ...
PARP1 Olaparib Competitive Inhibitor Assay Kit PARP1 82293
2022AACR | AZ首爆新一代PARPi人体临床试验数据，直击安全性痛点，对多癌种有效-世展网
Abstract ND05: Discovery and first structural disclosure of AZD5305: A ...
saruparib (AZD5305) / AstraZeneca
(PDF) Preclinical Characterization of AZD5305, A Next-Generation ...
2022 AACR | 小分子领域：合成致死细化&PARP-1深度开发！__财经头条
阿斯利康的PARP抑制剂如何差异化？
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody ...
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA ...
恒瑞PARP1抑制剂HRS-1167出海带来的思考
阿斯利康第二代PARP抑制劑AZD5305申報臨床 - 每日頭條
阿斯利康的PARP抑制剂如何差异化？|阿斯利康|奥拉帕利|抑制剂|卵巢癌|适应症|-健康界
恒瑞PARP1抑制剂HRS-1167出海带来的思考 - 知乎
AZD5305|CAS 2589531-76-8|DC Chemicals
Abstract B070: Antitumor effect of AZD5305, a selective PARP1 inhibitor ...
B7H4 ADC + PARPi + PD-1/TIGIT 双抗，三联疗法国内获批临床_Insight_开发_治疗
80551 | PARP1 Chemiluminescent Assay Kit Clinisciences
前列腺癌新药临床试验：PARP1抑制剂Saruparib（AZD5305）-印塔健康官网
阿斯利康第二代PARP1抑制剂AZD5305联合AZD9833治疗BRCA或PALB2突变的晚期乳腺癌患者 - 知乎
PARP抑制剂：氟唑帕利、帕米帕利、AZD5305对比-觅健
阿斯利康第二代PARP抑制剂AZD5305申报临床 7月6日，CDE官网显示， 阿斯利康 第二代PARP（高选择性PARP1）抑制剂 ...
A unified mechanism for PARP inhibitor-induced PARP1 chromatin ...
【速递】PARP1抑制剂，恒瑞携手国际大药厂走向国际市场医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康第二代PARP抑制剂AZD5305申报临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康国内首申下一代PARP抑制剂，有望克服旧产品副作用|阿斯利康_新浪财经_新浪网
PARP抑制剂 | PARP Inhibitor
阿斯利康申报下一代 PARP 抑制剂，接棒“重磅炸弹”奥拉帕利 7 月 6 日，CDE 官网显示， 阿斯利康 在国内申报了继奥拉帕利之后的第二 ...
